Ventus has an emerging pipeline of small molecule medicines to treat inflammatory and immune-related diseases, cancer and neurological disorders. Our lead programs address proteins of the innate immune system, targeting the inflammasome and nucleic acid sensing pathways. We have multiple programs in the hit to lead or lead optimization phase and are pursuing a broad pipeline of additional targets.